WEST COLUMIBA, S.C., March 13, 2018 /PRNewswire/ — Nephron Pharmaceuticals Corporation (Nephron) is announcing their partnership with Apprenticeship Carolina, a division of the SC Technical College System dedicated to increasing the awareness and use of registered apprenticeships in South Carolina.
The program provides nine Nephron employees the opportunity to earn a Community Pharmacy Technician certificate at Midlands Technical College (MTC). The MTC Pharmacy Technician program teaches students proper pharmacy operations under the supervision of registered pharmacists, and combines classroom, online and experiential learning into a well-balanced program of study. Participants will receive a paid-for education while continuing to work, allowing them to earn money and gather on-the-job training and knowledge.
“We are so thrilled to give our employees the opportunity to go back to school and earn a certification while still working at Nephron,” said Lou Kennedy, CEO at Nephron. “We are always excited to partner with our friends at Midlands Tech. This is how we make it happen.”
The first nine apprentices will launch the pilot program; however the company will select additional employees to participate in the future. The classes and degrees offered will also expand over time.
Nephron became registered with the United States Department of Labor on January 8, 2018, making the company an official employee sponsor for Apprenticeship Carolina.
Funding from the SCAI Grant (South Carolina Apprenticeship Initiative) covers a portion of the MTC course for each student, and Nephron will supply all additional costs. Nephron was able to receive this grant through their partnership with Apprenticeship Carolina.
The program taking place at MTC will extend over five months, and it began on March 6, 2018.
To learn more about:
CONTACT: Wesley Mitchell, email@example.com, (800) 443-4313
View original content with multimedia:http://www.prnewswire.com/news-releases/free-apprenticeships-provided-by-nephron-pharmaceuticals-corporation-300613501.html
SOURCE Nephron Pharmaceuticals Corporation
To post and circulate your own press release on FIR and the eTN Network please click here